If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Paul T. Finger, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialties: Retinal Ophthalmology, Ophthalmology, Ocular Oncology
  • Treats: Adults
  • Languages: English, Russian, Spanish
  • Phone: 212-832-8170
View Locations

Conditions and Treatments

Conditions
  • intraocular melanoma
  • retinoblastoma
  • squamous cell cancer
Treatments
  • excision of melanoma
  • eye surgery
  • ocular surface tumor removal
  • radiation therapy

Board Certifications
  • American Board of Ophthalmology - Ophthalmology, 1990
Education and Training
  • Fellowship, North Shore University Hospital - Manhasset, Ocular Oncology, 1987
  • Residency, Manhattan Eye, Ear and Throat Hospital, Ophthalmology, 1986
  • MD from Tulane University, 1982

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Paul T. Finger, MD does not accept insurance.

Locations and Appointments

The New York Eye Cancer Center

115 East 61st Street, New York, NY 10065

Phone

212-832-8170

Fax

212-888-4030

Interests

eye cancer, eye and orbit radiation therapy, orbital Disease, small incision biopsy

Research Summary

My career would not have been possible without my fellowship/apprenticeship experience with Samuel Packer MD, writing numerous systematic reviews of the literature, investigational learning to support my inventions/innovations in ophthalmic oncology, and desire to stretch the limits of patient care to provide excellent outcomes. 

Subsequent highlights of my innovations include the discovery of palladium-103 plaque therapy for intraocular tumors, topical chemotherapy (mitomycin and interferon) “eye drops” for conjunctival melanoma, and new eye and vision sparing radiation methods and devices for cancers located anteriorly in the iris or posteriorly around the optic nerve. In 2007, I first reported anti-VEGF treatment to suppress radiation retinopathy and anterior optic neuropathy. This method is widely used, saving vision around the world.

In terms of new methods of diagnosis, my published research efforts include 3D-ultrasound techniques to reveal previously obscure areas of the eye, optic nerve, and orbit. Out of necessity, I established normative high frequency ultrasound measurements for the iris and ciliary body. Other contributions were typically published to support my fellows and residents. We have published on whole-body PET-CT to diagnose and stage ocular melanoma, orbital lymphoma, sebaceous carcinoma, and conjunctival melanoma as well as  evaluated SUV as a biomarker for choroidal melanoma metastasis. In other works, we showed that PET-CT can be used to discover and stage systemic metastasis to the eye, reveal oculosystemic sarcoidosis, and evaluate choroidal melanoma response to ophthalmic radiation therapy. Separately, I recognized that using available small-gauge aspiration cutter technology would allow for safer, self-sealing micro-incisional biopsies. This clinical research generated publications on the “Finger Iridectomy Technique (FIT)” as well as the “Finger Aspiration Cutter Technique (FACT)” for orbital tumors.

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Read All Publications (247)